Treatment Patterns Among Adults with Primary Immune Thrombocytopenia Diagnosed in Hematology Clinics in the United States

The treatment landscape for primary immune thrombocytopenia had expanded with thrombopoietin receptor agonists, but real-world patterns of treatment sequencing, duration, and switching had not been systematically described in a large hematology clinic dataset.

Target RWE researchers characterized treatment patterns among adults with ITP diagnosed in US hematology clinics using real-world data, describing sequences of conventional and novel agents, duration of therapy, and predictors of treatment modification.

Documenting real-world ITP treatment sequencing patterns provides Amgen and other hematology sponsors with natural history and competitive context needed to design effectiveness studies and position novel ITP therapies.

ITP treatment sequencing and switching patterns for hematology drug development competitive context, Real-world treatment duration evidence for ITP therapy positioning and label strategy